

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this notice, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this notice.



LANSEN PHARMACEUTICAL HOLDINGS LIMITED
朗生醫藥控股有限公司

(incorporated in the Cayman Islands with limited liability)

(Stock code: 503)

NOTICE OF EXTRAORDINARY GENERAL MEETING

NOTICE IS HEREBY GIVEN that an extraordinary general meeting (the “**General Meeting**”) of Lansan Pharmaceutical Holdings Limited 朗生醫藥控股有限公司 (the “**Company**”) will be held at The Executive Centre, Level 35, Two Pacific Place, No. 88 Queensway, Admiralty, Hong Kong on Monday, 27 November 2023 at 10:30 a.m. (Hong Kong time) (or, if later, as soon as practicable after the conclusion or the adjournment of the Court Meeting (as defined in the Scheme Document (as defined below)) for the purpose of considering and, if thought fit, passing the following resolution:

SPECIAL RESOLUTION

“**THAT:**

1. for the purpose of giving effect to the scheme of arrangement between the Company and the Scheme Shareholders (as defined in the Scheme Document, as defined further below) (the “**Scheme**”) as set out in the scheme document of the Company dated 28 October 2023 (the “**Scheme Document**”) and subject to the approval of the Scheme by the Scheme Shareholders at the Court Meeting (as defined in the Scheme Document), on the Effective Date (as defined in the Scheme Document), any reduction of the issued share capital of the Company associated with the cancellation and extinguishment of the Scheme Shares (as defined in the Scheme Document) be and is hereby approved;
2. subject to and simultaneously with the cancellation and extinguishment of the Scheme Shares, the maintenance of the issued share capital of the Company at the amount prior to the cancellation and extinguishment of the Scheme Shares by applying the credit created as a result of the aforesaid cancellation and extinguishment of the Scheme Shares to pay up in full at par such number of new Shares (as defined in the Scheme Document) as is equal to the number of Scheme Shares cancelled for allotment and issuance to Cathay International Pharma Manufacture and Distribution (China) Limited be and is hereby approved; and that the directors of the Company be and are hereby authorised to allot and issue such new Shares accordingly;
3. subject to the Scheme taking effect, the withdrawal of listing of the Shares on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) be and is hereby approved; and

4. the directors of the Company be and are hereby unconditionally authorised to do all acts and things and/or sign all such documents as considered by them to be necessary for or desirable in connection with the implementation of the Proposal (as defined in the Scheme Document) and the Scheme, including (without limitation) (i) the making of an application to the Stock Exchange for the withdrawal of the listing of the Shares on the Stock Exchange, subject to the Scheme taking effect; (ii) any reduction of the issued share capital of the Company; (iii) the allotment and issue of the Shares referred to above; and (iv) the giving, on behalf of the Company, of consent to any modification of, or addition to, the Scheme, which the Grand Court of the Cayman Islands may see fit to impose.”

By order of the Board
Lansen Pharmaceutical Holdings Limited
朗生醫藥控股有限公司
Wu Zhen Tao
Chairman

Hong Kong, 28 October 2023

Registered office:

Windward 3, Regatta Office Park
P.O. Box 1350
Grand Cayman
KY1-1108
Cayman Islands

Principal place of business in Hong Kong:

Suites 1203-4
12/F., Li Po Chun Chambers
189 Des Voeux Road Central
Hong Kong

Notes:

1. Unless otherwise indicated, expressions used herein shall have the same meanings as those defined in the scheme document of the Company dated 28 October 2023 (the “**Scheme Document**”), of which this notice forms part.
2. The above resolution will be voted upon by way of poll at the General Meeting in accordance with the articles of association of the Company, the Listing Rules and the Takeovers Code. The results of the poll will be published on the respective websites of the Stock Exchange and the Company in accordance with the Listing Rules and the Takeovers Code.
3. A shareholder entitled to attend and vote at the General Meeting shall be entitled to appoint another person as his/her proxy to attend and vote instead of him/her. A shareholder who is the holder of two or more shares of the Company may appoint more than one proxy to represent him/her and vote on his/her behalf at the General Meeting. A proxy need not be a shareholder of the Company but must attend the General Meeting in person in order to represent you.
4. In the case of joint holders of a share, any one of such persons may vote at the General Meeting, either personally or by proxy, in respect of such share as if she/he were solely entitled thereto; but if more than one of such joint holders be present at any meeting personally or by proxy, that one of the said persons so present whose name stands first on the register of members of the Company in respect of such share shall alone be entitled to vote in respect thereof.

5. In order to be valid, the duly completed and signed **WHITE** form of proxy, together with the power of attorney or other authority, if any, under which it is signed or a certified copy of that power of attorney or authority, must be deposited at the branch share registrar of the Company in Hong Kong, Link Market Services (Hong Kong) Pty Limited at Suite 1601, 16/F, Central Tower, 28 Queen's Road Central, Hong Kong not less than 48 hours before the time appointed for the holding of the General Meeting or any adjournment thereof. Completion and return of the **WHITE** form of proxy will not preclude a shareholder from attending and voting in person at the General Meeting if he/she so wishes and, in such event, the instrument appointing a proxy shall be revoked by operation of law.
6. For the purpose of determining the entitlements of the shareholders to attend and vote at the General Meeting, the register of members of the Company will be closed from Monday, 20 November 2023 to Monday 27 November 2023 (both days inclusive) and during such period, no transfer of shares will be effected. In order to qualify to vote at the General Meeting, all transfer documents accompanied by the relevant share certificates must be lodged with the Company's branch share registrar in Hong Kong, Link Market Services (Hong Kong) Pty Limited at Suite 1601, 16/F, Central Tower, 28 Queen's Road Central, Hong Kong before 4:30 p.m. on Friday, 17 November 2023.
7. A **WHITE** form of proxy for use at the General Meeting is enclosed with the Scheme Document. Such form is also published on the website of the Stock Exchange at www.hkexnews.hk and on the website of the Company at www.lansen.com.cn.
8. References to time and dates in this notice are to Hong Kong time and dates.

As at the date of this notice, the Board comprises Mr. Chen Li being the executive managing Director, Mr. Wu Zhen Tao and Ms. Liu Xuezi being the non-executive Directors, and Mr. Chan Kee Huen, Michael, Mr. Yeung Tak Bun, Allen, Ms. Chan Ching Har, Eliza and Dr. Zhu Xun being the independent non-executive Directors.